Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database

Delanoy, Nicolas; Hardy-Bessard, Anne Claire; Efstathiou, Eleni; Moulec, Sylvestre Le; Basso, Umberto; Birtle, Alison; Thomson, Alastair; Krainer, Michael; Guillot, Aline; Giorgi, Ugo De; Hasbini, Ali; Daugaard, Gedske; Bahl, Amit; Chowdhury, Simon; Caffo, Orazio; Beuzeboc, Philippe; Spaeth, Dominique; Eymard, Jean Christophe; Fléchon, Aude; Alexandre, Jérôme; Hélissey, Carole; Butt, Mohamed; Priou, Frank; Lechevallier, É.; Deville, Jean Laurent; Goupil, Marine Gross; Morales, Rafael; Thiery-Vuillemin, A.; Gavrikova, Tatiana; Barthélémy, Philippe; Sella, Avishay; Fizazi, Karim; Baciarello, Giulia; Fererro, Jean Marc; Laguerre, Brigitte; Verret, Benjamin; Hans, Sophie; Oudard, Stéphane

doi:10.1016/j.euo.2018.05.009

Cited by 28 publications

(22 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Typically, metastatic disease developed after an initial period of locally or locoregionally confined cancer. These characteristics resemble those reported in other studies from nonarctic regions [4,5,12].…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Is there a seasonal variation of survival after systemic chemotherapy for metastatic castration-resistant prostate cancer in a rural part of North Norway?

Nieder

Dalhaug

Haukland

2020

International Journal of Circumpolar Health

View full text Add to dashboard Cite

The winter darkness or polar night induces endocrine and metabolic mechanisms, which might reduce the efficacy of cancer treatment and thus contribute to shorter survival. Moreover, seasonand weather-related treatment delays and irregularities might also cause reduced efficacy of anticancer drugs. Therefore, this study evaluated the prognostic impact of timing of chemotherapy (start during winter darkness or outside of this season), in terms of overall survival, in patients with metastatic castration-resistant prostate cancer (MCRPC) who received oncology care at the Nordland hospital Bodø. The study included 111 patients treated with first-line docetaxel chemotherapy for MCRPC. Twenty patients (18%) started their treatment during winter darkness (arbitrarily defined as ±4 weeks around 21 December). In unadjusted univariate analysis, survival was shorter in this group (median 10.2 vs. 18.9 months, p = 0.055). However, not all baseline parameters were equally distributed between the two groups. In multivariable-adjusted Cox regression analysis accounting for several confounding variables, only one factor was statistically significant: pre-chemotherapy serum lactate dehydrogenase level (a surrogate marker of disease burden). Thus, the present results suggest that seasonal variation is not a major contributor to the diverging survival outcomes observed after docetaxel chemotherapy.

show abstract

Section: Discussionsupporting

confidence: 90%

“…Commonly, patients with performance status 0-1 (corresponding to Karnofsky score 80-100) and without contraindications to one or several of these approved drugs receive sequential treatment [4,5]. There is no universally agreed sequence of choice.…”

Section: Introductionmentioning

confidence: 99%

Is there a seasonal variation of survival after systemic chemotherapy for metastatic castration-resistant prostate cancer in a rural part of North Norway?

Nieder

Dalhaug

Haukland

2020

International Journal of Circumpolar Health

View full text Add to dashboard Cite

show abstract

“…First, this was a retrospective and unplanned analysis of VENICE, TAX327 and FIRST-ANA. Second, this study only applies to patients with mCRPC treated with first-line chemotherapy, although the results could be applicable to daily practice [26,27] and to the design of therapeutic trials [26,27]. Third, the TAX-327 and VENICE trials were conducted before the clinical availability of abiraterone, enzalutamide, radium-223 and CAB, which may have confounded the survival analyses.…”

Section: Discussionmentioning

confidence: 99%

Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials

Robbrecht

Delanoy

Tannock³

et al. 2020

European Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Background: There is a discussion about the optimal timing to initiate or switch treatment in metastatic castration-resistant prostate cancer (mCRPC). This post hoc analysis of 3 large trials for men with mCRPC examined the influence of the type of progression at initiation of first-line chemotherapy, as well as the type of progression during treatment, on treatment outcomes. Methods: Data from the phase III studies VENICE (n Z 1224), TAX327 (n Z 1006) and FIRSTANA (n Z 1168) were used as independent data sets. Type of progression was defined as follows: prostate-specific antigen (PSA) only (group 1), radiological (AEPSA) (group 2) or pain (AEPSA, AE radiological) progression (group 3). The impact of baseline type of progression on overall survival (OS) was evaluated in multivariate Cox regression analysis with backward elimination, stratified for the Eastern Cooperative Oncology Group performance score and treatment arm. Results: The median OS (arms combined) from treatment initiation in VENICE was 28.6, 26.3 and 16.9 months for G1, G2 and G3, respectively (hazard ratio: 1.14 [95% confidence interval

show abstract

“…Chemotherapy regimens for mCRPC improve overall survival in patients with mCRPC [1][2][3]. Docetaxel is a first line chemotherapy regimen for mCRPC with good overall response rates [4], and is more recently employed in the management of newly diagnosed metastatic hormone sensitive prostate cancer.…”

Section: Introductionmentioning

confidence: 99%

WITHDRAWN: Exploratory Study of [18F]fluciclovine PET/CT for Response Assessment to Docetaxel in Patients with Metastatic Castration Resistant Prostate Cancer

Akintayo

Bilen

Abiodun-Ojo

et al. 2020

Preprint

View full text Add to dashboard Cite

Background The ability to accurately monitor response to treatment in patients with metastatic castration resistant prostate cancer (mCRPC) on chemotherapy has been a challenge. Conventional methods of therapy response assessment have limitations and molecular imaging has been explored as an important alternative. We set out t o determine if anti-1-amino-3-anti-1-amino-3-[18F]-fluorocyclobutane-1-carboxylic acid ([18F]fluciclovine) positron emission tomography/computed tomography (PET/CT) changes reflect response to docetaxel chemotherapy in mCRPC. Results Seven patients with mCRPC were enrolled. Each patient was scheduled to have [18F]fluciclovine PET/CT at baseline, and after 1 and 6 cycles of chemotherapy. Uptake parameters were recorded in the prostate/bed and up to 10 metastatic lesions. Decrease in uptake of ≥30% was considered response (R); appearance of new lesions or >30% increase in uptake was progressive disease (PD); and change of < 30% uptake was stable disease (SD). Prostate specific antigen (PSA) was obtained at baseline and before each cycle. Bone scintigraphy and CT were acquired at baseline and after the 6th cycle. Assessment of response was based on Prostate Cancer Clinical Trial Working Group 3 recommendations. Correlation between [18F]fluciclovine uptake and time to PSA progression was also determined. All patients completed the 1 st and 2 nd [18F]fluciclovine PET/CT, while 4/7 patients completed all 3 scans. PET response correlated with PSA response in 3/7 (42.9%) patients and 3/4 (75%) patients after 1 and 6 cycles of docetaxel, respectively. Bone scan and CT correlated with PSA response in 1/4 (25%) patients. Mean SUVmax and SUVmean were significantly higher in patients with progressive disease versus non-progressive disease after 6 cycles of docetaxel (p<0.05), but not at baseline or after 1 cycle of docetaxel. There was non-significant correlation of changes in [18F]fluciclovine uptake with changes in PSA after 1 and 6 cycles of docetaxel. There was no significant correlation between PET parameters and time to PSA progression. Conclusion [18F]fluciclovine PET/CT has better correlation than CT or bone scan with PSA response for patients with mCRPC treated with docetaxel. [18F]fluciclovine PET/CT did not predict time to PSA progression. Larger studies exploring the utility of [18F]fluciclovine PET for response assessment are recommended.

show abstract

Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database

Cited by 28 publications

References 30 publications

Is there a seasonal variation of survival after systemic chemotherapy for metastatic castration-resistant prostate cancer in a rural part of North Norway?

Is there a seasonal variation of survival after systemic chemotherapy for metastatic castration-resistant prostate cancer in a rural part of North Norway?

Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials

WITHDRAWN: Exploratory Study of [18F]fluciclovine PET/CT for Response Assessment to Docetaxel in Patients with Metastatic Castration Resistant Prostate Cancer

Contact Info

Product

Resources

About